The Lancet Infectious Diseases in conversation with podcast

Prasad Kulkarni on dengue monoclonal antibodies

0:00
18:53
Spola tillbaka 15 sekunder
Spola framåt 15 sekunder

Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.

Read the full article:
https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Fler avsnitt från "The Lancet Infectious Diseases in conversation with"